key: cord-0693654-qrccc4l6 authors: Santos-Araújo, Carla; Veiga, Pedro Mota; Santos, Mário João; Santos, Lidia; Romãozinho, Catarina; Silva, Mónica; Lucas, Carlos; Duarte, Mary Luz; Haarhaus, Mathias; Haase, Michael; Macário, Fernando title: Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in hemodialysis patients: a multicenter study date: 2021-10-11 journal: Nephrol Dial Transplant DOI: 10.1093/ndt/gfab293 sha: b4b2f08c6df335c95370cea7fd60815475ccb491 doc_id: 693654 cord_uid: qrccc4l6 BACKGROUND: Vaccination programs are essential for the containment of the COVID-19 pandemic, which has affected hemodialysis populations especially hard. Early reports suggest a reduced immunologic response to SARS-Cov-2 vaccines in dialysis patients, in spite of a high degree of seroconversion. We aimed to identify risk factors for a reduced efficacy of an mRNA vaccine in a cohort of hemodialysis patients. METHOD: In a multicenter study, including 294 Portuguese hemodialysis patients who had received 2 doses of BNT162b2 with a three week interval, IgG-class antibodies against the SARS-CoV-2 spike protein were determined 3 weeks after the first dose (M1) and 6 weeks after the second dose (M2). The threshold for seroconversion was 10UR/mL. Demographic and clinical data was retrieved from a quality registry. Adverse events were registered using a questionnaire. RESULTS: At M2, seroconversion was 93.1% with a median antibody level of 197.5U/mL (1.2–3237.0) and a median increase of 180.0U/mL (-82.9–2244.6) from M1. Age (beta -8.9; 95%CI: -12.88 to -4.91; P < 0.0001), ferritin > 600ng/mL (beta 183.93; 95%CI: 74.75 to 293.10; P = 0.001) and physical activity (beta 265.79; 95%CI: 30.7 to 500.88; P = 0.03) were independent predictors of SARS-Cov-2 antibody levels after two vaccine doses. Plasma albumin > 3.5g/dL independently predicted the increase of antibody levels between both doses (OR 14.72; 95%CI: 1.38 to 157.45; P = 0.03). Only mild adverse reactions were observed in 10.9% of patients. CONCLUSIONS: The SARS-Cov-2 vaccine BNT162b2 is safe and effective in hemodialysis patients. Besides age, iron status and nutrition are possible modifiable modulators of the immunologic response to SARS-Cov-2 mRNA vaccines. This data suggests the need for an early identification of populations at higher risk for diminished antibody production and the potential advantage of the implementation of oriented strategies to maximize the immune response to vaccination in these patients. What this study adds?  In our cohort of hemodialysis patients, we have documented a substantial humoral response to the SARS-Cov-2 BNT162b2 vaccine, more impressive after the second dose and still evident six weeks after the last inoculation.  Vaccination with BNT162b2 vaccine was well tolerated in our cohort, with an overall adverse event incidence of 10.9% and all incidents registered mild and self-limited.  Younger age and two modifiable factors -higher albumin and ferritin plasma levels, were identified as independent predictors of antibody levels after the first and the second vaccine doses and of a greater increase in antibody levels between doses. What impact this may have on practice or policy?  The significant increase in the number of responders from the first to the second vaccine doses may preclude the potential benefit of subsequent exposures of the patient immune system to additional vaccine administrations.  Early identification of the dialysis population exposed at the higher risk of a damped immune response to vaccination may help to implement strategies to monitor and take full advantage of seroconversion.  Some of these strategies may include improving iron status and adjust nutritional support before the vaccination protocol. Chronic kidney disease (CKD), and particularly dialysis, have emerged as the most prevalent conditions conveying risk for both severe disease and death from COVID19 (1,2) . Indeed, several studies performed on hemodialysis patients report significantly higher infection rates, when compared with the general population (3, 4) , and a short-term mortality rate above 20% (5) . Vaccination, through the reduction in infection rate, mortality and health care system burden, has presented for all health care groups as one of the cornerstones of COVID19 management. Despite prior evidence in CKD patients of significant seroconversion with other type of vaccines, the need for larger doses to elicit an adequate immune response had sometimes motivated the adaptation of immunization protocols in this population (6) . Previous studies have reported the presence of SARS-Cov-2 IgG antibodies around two months after COVID19 infection in CKD patients (7), but data regarding safety and efficacy of SARS-Cov-2 vaccines and the time-dependent evolution of antibody titers during the vaccination process in this population are still scarce. The aim of our work was to evaluate the evolution of the prevalence of SARS-Cov-2 IgG antibodies in a population of hemodialysis patients after the first and second doses of an mRNA based SARS-Cov-2 vaccine. This is a multicenter, prospective, observational study, including patients aged >18 years old randomized from a national hemodialysis cohort admitted permanently for dialysis for at least 3 months and submitted to 2 doses of BNT162b2 vaccine, 21 days apart. The list of participating centres is presented as supplementary material (Supplementary Table 1 ). Patients with a previous diagnosis of COVID19 or unable to give informed consent were excluded. The demographic and clinical data, dialysis-specific parameters, and information about medications were obtained from our Renal Information Management System (iRIMS). Baseline laboratory data was obtained from the last month before immunization. Adverse events were also collected, through a specific form conceived for this purpose. The study was approved by the Diaverum National Ethics Committee and written informed consent was obtained from all the participants. Blood samples were collected using BD Vacutainer R tubes No. 367955 just before and 6 weeks after the second administration. After centrifugation, serum samples were stored at -20ºC until processed. For the quantitative determination of human IgG-class antibodies, an immunoenzymatic method was applied to the S1 domain of the SARS-CoV-2 spike protein (Anti-SARS-CoV-2 Quantivac ELISA (IgG), EUROIMMUN R, ref. nº EI 2606-9601-10 G). The method was performed according to the manufacturer's recommendations and a cut-off of 10 UR/mL was used to define immunologic response. Sample size was calculated for a sampling error of 3%, a 95% confidence level and an estimated proportion of patients with protective antibody levels of 95%. For categorical variables, we calculated frequencies and proportions; for numerical variables, we calculated the median and interquartile range. We compared categorical variables by prevalence and level of SARS-Cov-2 spike protein IgG antibodies using the chi-square test, or Fisher's exact test as appropriate. We used the Mann-Whitney test and Kruskal-Wallis test to compare numerical variables. We used multivariable logistic regression models and multivariable linear regression models to determine independent factors that explain the prevalence of responders vs. nonresponders and the levels of SARS-Cov-2 IgG antibodies (U/mL), respectively. In multivariate analysis we included all variables with a p<0.2 in the univariate analyses. We considered p values of less than 0.05 to be statistically significant. We analyzed all data using IBM-SPSS, version 27.0. The study included 294 patients: 281 valid samples were analyzed in the first antibody determination and 262 in the second evaluation. In 249 patients, two serial antibody determinations were obtained (Supplementary Figure 1 ). The list of participating centres is listed on Supplementary Table 1 . Baseline characteristics of the total population studied are listed in Supplementary Table 2 . We Univariate analysis is described in Supplementary independent predictors of SARS-Cov-2 antibody levels ( Table 2) . Univariate analysis is described in Supplementary Table 3 for the difference in IgG levels between the two antibody determinations. In multivariate analysis, a plasma albumin level above 3.5g/dl was identified as an independent predictor of a greater increase in antibody levels between the two vaccinations (beta 0.44; 95%CI: 0.09 to 0.78; p=0.013) ( Table 2) . Adverse events to BNT162b2 vaccine are reported in Supplementary Tables 4 In our cohort of hemodialysis patients, we have documented a substantial humoral response to two consecutive doses of the SARS-Cov-2 BNT162b2 vaccine. Younger age and higher albumin and ferritin plasma levels were identified as independent predictors of antibody levels after both the first and the second vaccine doses. The potency of approved SARS-Cov-2 vaccines in immune compromised individuals is currently unknown, as patients with significant underlying medical conditions, including CKD, were excluded from the efficacy studies performed so far (8) . This is particularly relevant if we consider that a reduced immune response to infection or vaccination has repeatedly been described in hemodialysis patients (9, 10, 11) . In fact, this finding served as a rationale for dose or schedule changes in several vaccination programs for this population in the past (12) . In our cohort, a significant humoral response was observed, with 93.1% of the patients presenting SARS-Cov-2 antibody levels above the defined threshold of 10 UR/mL, six weeks after the administration of the second dose of the vaccine. The median antibody level was almost 20fold above the threshold. This finding is in accordance with previous reports and confirms the efficacy of vaccination in this subgroup of patients (13, 14, 15) . However, this humoral response may be inferior to that observed in the general population (16, 17) , which may justify in these Further studies evaluating the long-term antibody persistence after the vaccination may help to elucidate this point. In our study, patients with a plasma albumin concentration above 3.5g/dL and a ferritin level above 600ng/ml were more likely to respond to the first vaccination dose and to have a higher antibody increase between administrations. Additionally, and in agreement with other reports (16, 17) , a negative correlation was observed in our group between age and SARS-Cov-2 antibody levels. Plasma albumin is related to the patient nutritional status and reduced levels may be associated with decreased antibody response to immunization in dialysis patients (19, 20) . Our study is the first report of an association of increased plasma ferritin with an improved immune response to SARS-Cov-2 vaccine in hemodialysis patients, which is in line with previous findings with influenza vaccination (21) . Iron status is a modulator of immune reactivity (22) and iron supplementation may improve vaccination response (23) . Improving nutritional status can be challenging in dialysis patients, particularly in the elderly, but the early identification of the dialysis population exposed at the higher risk of a damped immune response to vaccination may help to implement strategies to monitor and take full advantage of seroconversion. Some of these strategies may include improving iron status and adjust nutritional support before the vaccination protocol. Vaccination with BNT162b2 vaccine was well tolerated in our cohort, with an overall adverse event incidence of 10.9%. This is in accordance with previous descriptions in this population (24, 25) . Despite the significantly higher report rate after the second administration when compared to the first vaccine dose, all incidents registered were mild and self-limited. Additionally, we had no hospitalizations related to the vaccination process and almost all patients recovered. Interestingly, a significant association was observed between adverse event occurrence and therapy with angiotensin 2 antagonists. As far as we now, this is the first time that this association is described and further evaluation is needed. Our study had several limitations. Despite the fact that all patients with a previous history of COVID19 were excluded, no antibody determination was performed before the administration of the first dose of the vaccine and we cannot surely affirm that all the serologic responses were in fact due to vaccination. However, our patients were routinely screened with SARS-CoV-2 PCR tests, whenever a positive contact was identified. Additionally, no control group was included and we cannot compare the efficacy and amplitude of serologic response with patients without terminal kidney disease. In conclusion, our study demonstrates that BNT162b2 vaccine is safe and effective in a cohort of multicenter hemodialysis patients. Besides increased age, modifiable risk factors for a reduced vaccine efficacy, such as low albumin and ferritin levels were identified, suggesting an impact of malnutrition and iron status on the incidence and amplitude of the immunologic response to the vaccine. This data suggests the need for an early identification of populations at higher risk for diminished antibody production and the potential advantage of the implementation of oriented strategies to maximize the immune response to vaccination in these patients. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a region wide registry study Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARSCoV-2: a UK Renal Registry data analysis Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis COVID-19 vaccines and kidney disease Immune cell dysfunction and inflammation in end-stage renal disease Aspects of immune dysfunction in end-stage renal disease Immunogenicity of a first dose of mRNA-or vector-based SARS-CoV-2 vaccination in dialysis patients: A multicenter prospective observational pilot study Hepatitis B virus vaccine immune response and mortality in dialysis patients: A meta-analysis Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients The Safety and Immunogenicity of the mRNA Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis Iron Metabolism at the Interface between Host and Pathogen: From Nutritional Immunity to Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial Iron Deficiency Anemia at Time of Vaccination Predicts Decreased Vaccine Response and Iron Supplementation at Time of Vaccination Increases Humoral Vaccine Response: A Birth Cohort Study and a Randomized Trial Follow-Up Study in Kenyan Infants Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients -a prospective cohort study Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort We want to thank all participating patients and health care personnel from Diaverum Portugal. FM supervised the study. All authors contributed to the interpretation of data and read and approved the final manuscript. All authors had unrestricted access to all data in the study.